Is Cytomegalovirus Linked to Childhood Leukemia Risk?

Article

Prenatal infection with cytomegalovirus increases the risk of childhood acute lymphoblastic leukemia, indicates a study of newborn blood and pretreatment childhood bone marrow published in the journal Blood.

Prenatal infection with cytomegalovirus (CMV) increases the risk of childhood acute lymphoblastic leukemia (ALL), indicates a study of newborn blood and pretreatment childhood bone marrow published in the journal Blood.

The finding suggests the possibility that ALL could be prevented with antiviral interventions or vaccination.

“If it’s truly that in utero CMV is one of the initiating events in the development of childhood leukemia, then control of the virus has the potential to be a prevention target,” said lead study author Stephen Francis, PhD, assistant professor of epidemiology at the University of Nevada and University of California San Francisco.

Using archived pretreatment bone marrow samples from the California Childhood Leukemia Study at UC Berkeley, the researchers conducted a comprehensive untargeted search for bacteria and all known viruses in marrow from 38 children with acute myeloid leukemia (AML) and 127 children diagnosed with ALL.

Marrow from all of the children with ALL harbored CMV DNA, they discovered. Active CMV transcription was demonstrated in leukemia blasts and intact CMV virions were found in serum.

The research team subsequently screened newborn blood-spot samples for CMV among 268 children who were later diagnosed with ALL and 270 healthy control children. Children who developed ALL were more than three times as likely to have been CMV-positive at birth (odds ratio [OR] 3.71, 95% CI: 1.56-792; P = .0016).

The association between in-utero CMV infection and subsequent development of ALL was particularly strong among Hispanic children (OR 5.90; 95% CI: 1.89-25.96; P = .006).

“This is the first step, but if we do end up finding a causal link to the most common childhood cancer, we hope that will light a fire in terms of stopping mother-to-child transmission of CMV,” said Francis.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Related Content